PharmaShots Weekly Snapshots (November 14 – November 17, 2023)

Share this

PharmaShots Weekly Snapshots (November 14 – November 17, 2023)

This week PharmaShots’ news was all about the updates on  regulatory, M&A   pharma, and Clinical Trials . Check out our full report below:

AstraZeneca’s Imfinzi + CT Received NMPA Approval for the treatment of Locally Advanced/metastatic Biliary Tract Cancer  

Read More: AstraZeneca                                                                     

Roche received the EU’s CHMP Positive Opinion for the approval of subcutaneous injection of Tecentriq 

Read More: Roche                                                                               

BMS Receives the US FDA’s Approval for Augtyro (repotrectinib) to Treat Non-Small Cell Lung Cancer (NSCLC)

Read More: BMS                                                                                     

The European Commission Approved argenx’s Vyvgart with Halozyme’s Enhanze for the Treatment of Generalized Myasthenia Gravis

Read More: argenx & Halozyme                                                           

Praxis Precision's elsunersen has been awarded the PRIME (PRIority MEdicines) designation by the European Medicines Agency (EMA) for the treatment of SCN2A developmental and epileptic encephalopathy (SCN2A-DEE)

 Read More: Praxis Precision                                                             

Ajinomoto to acquire Forge Biologics for $620M

Read More: Ajinomoto & Forge Biologics                                         

For ~$175 million, Astellas acquires Propella Therapeutics

Read More: Astellas & Propella Therapeutics                                    

The US FDA Approved Cormedix’s DefenCath for the Reduction of Catheter-Related Bloodstream Infections (CRBSI) In Adult Hemodialysis Patients

Read More: Cormedix                                                                               

For ~$180 million, GTCR to Acquire Cloudbreak Health

Read More: GTCR                                                                                     

Q32 Bio Re-Acquires the Rights to Bempikibart (ADX-914) for Autoimmune Diseases from Amgen

Read More: Q32 Bio                                                                             

Intercept Pharmaceutical highlights the P-II trial  results for OCA + Bezafibrate to treat PBC-Induced Liver Damage

Read More: Intercept Pharmaceutical                                                

Kite (Gilead) Expands its Collaboration Agreement with Arcellx for CART-DdBCMA to Treat Multiple Myeloma

Read More: Kite & Arcellx                                                                     

New data presented at AHA 2023 for zodasiran  by Arrowhead

Read More: Arrowhead                                                                           

New data presented at AHA 2023 for plozasiran  by Arrowhead 

Read More: Arrowhead                                                                

Vertex and CRISPR Therapeutics Received Conditional Marketing Authorization for Casgevy by the United Kingdom MHRA to Treat Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

Read More: Vertex & CRISPR Therapeutics                               

Tonix Pharmaceuticals Highlights the P-III Trial Results of TNX-102 SL for the Management of Fibromyalgia 

Read More: Tonix Pharmaceuticals                                             

SpringWorks Therapeutics Highlights the P-IIb Trial Results for Mirdametinib to Treat Neurofibromatosis Type 1-Associated Plexiform Neurofibromas (NF1-PN)

Read More: SpringWorks Therapeutics                                       

AbbVie Publishes the P-III Trial Results for Ubrelvy (ubrogepant) as Treatment for Migraine in ‘The Lancet’

Read More: AbbVie                          

Related Post:- PharmaShots Weekly Snapshots (November 06–10, 2023)                                           

Disha Nankani

Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions